Goldman Sachs’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-4,000
Closed -$1.4M 6621
2025
Q4
$1.4M Sell
4,000
-4,000
-50% -$1.35M ﹤0.01% 4879
2025
Q3
$2.58M Sell
8,000
-6,300
-44% -$1.96M ﹤0.01% 4263
2025
Q2
$5.56M Sell
14,300
-2,100
-13% -$845K ﹤0.01% 3312
2025
Q1
$7.13M Sell
16,400
-19,500
-54% -$7.83M ﹤0.01% 3010
2024
Q4
$13.2M Sell
35,900
-15,700
-30% -$6.57M ﹤0.01% 2531
2024
Q3
$26.8M Buy
51,600
+4,900
+10% +$2.62M ﹤0.01% 1791
2024
Q2
$25.3M Sell
46,700
-29,200
-38% -$15.4M ﹤0.01% 1695
2024
Q1
$39.4M Buy
75,900
+10,500
+16% +$5.22M 0.01% 1318
2023
Q4
$30.8M Buy
65,400
+13,900
+27% +$6.43M 0.01% 1532
2023
Q3
$22.4M Buy
+51,500
New +$23.4M ﹤0.01% 1694
2023
Q1
Sell
-1,600
Closed -$821K 6004
2022
Q4
$821K Sell
1,600
-7,100
-82% -$3.6M ﹤0.01% 4556
2022
Q3
$3.95M Sell
8,700
-2,500
-22% -$1.2M ﹤0.01% 3347
2022
Q2
$5.41M Buy
11,200
+3,700
+49% +$1.83M ﹤0.01% 3066
2022
Q1
$3.68M Sell
7,500
-6,000
-44% -$2.74M ﹤0.01% 3636
2021
Q4
$6.26M Buy
13,500
+2,700
+25% +$1.14M ﹤0.01% 3179
2021
Q3
$4.03M Buy
10,800
+3,700
+52% +$1.41M ﹤0.01% 3537
2021
Q2
$2.71M Buy
7,100
+4,000
+129% +$1.53M ﹤0.01% 3928
2021
Q1
$1.11M Sell
3,100
-12,700
-80% -$4.08M ﹤0.01% 4515
2020
Q4
$5.07M Buy
15,800
+6,500
+70% +$1.99M ﹤0.01% 2988
2020
Q3
$2.5M Sell
9,300
-9,600
-51% -$2.58M ﹤0.01% 3418
2020
Q2
$4.97M Buy
18,900
+2,700
+17% +$720K ﹤0.01% 2808
2020
Q1
$3.68M Buy
+16,200
New +$4.41M ﹤0.01% 2876
2019
Q3
Sell
-17,500
Closed -$4.94M 5213
2019
Q2
$4.94M Buy
+17,500
New +$4.78M ﹤0.01% 2854
2018
Q2
Sell
-35,000
Closed -$7.69M 5743
2018
Q1
$7.69M Buy
35,000
+27,600
+373% +$6.48M ﹤0.01% 2568
2017
Q4
$1.67M Sell
7,400
-33,900
-82% -$7.22M ﹤0.01% 3923
2017
Q3
$7.84M Sell
41,300
-13,600
-25% -$2.59M ﹤0.01% 2773
2017
Q2
$10.3M Buy
54,900
+38,400
+233% +$6.9M ﹤0.01% 2494
2017
Q1
$2.73M Buy
16,500
+200
+1% +$31.8K ﹤0.01% 3454
2016
Q4
$2.34M Sell
16,300
-39,700
-71% -$5.32M ﹤0.01% 3707
2016
Q3
$7.02M Buy
56,000
+54,900
+4,991% +$7.09M ﹤0.01% 2745
2016
Q2
$144K Buy
1,100
+1,000
+1,000% +$137K ﹤0.01% 5920
2016
Q1
$14K Sell
100
-3,800
-97% -$508K ﹤0.01% 6828
2015
Q4
$544K Sell
3,900
-1,700
-30% -$234K ﹤0.01% 4844
2015
Q3
$784K Sell
5,600
-11,500
-67% -$1.73M ﹤0.01% 4709
2015
Q2
$2.81M Sell
17,100
-7,400
-30% -$1.18M ﹤0.01% 3503
2015
Q1
$3.78M Sell
24,500
-53,300
-69% -$7.59M ﹤0.01% 3167
2014
Q4
$9.78M Buy
77,800
+6,100
+9% +$754K ﹤0.01% 2353
2014
Q3
$8.58M Sell
71,700
-37,300
-34% -$4.28M ﹤0.01% 2489
2014
Q2
$11.7M Sell
109,000
-12,500
-10% -$1.29M ﹤0.01% 2235
2014
Q1
$12.1M Sell
121,500
-238,900
-66% -$21.6M ﹤0.01% 2195
2013
Q4
$33.3M Sell
360,400
-5,800
-2% -$515K 0.01% 1362
2013
Q3
$30.6M Sell
366,200
-59,600
-14% -$5.11M 0.01% 1308
2013
Q2
$34.8M Buy
+425,800
New +$31.9M 0.01% 1135

Other funds holding ELV

Goldman Sachs's ELV Position: Q1 2026 in Review

Goldman Sachs reduced its Elevance Health (ELV) stake by 5.4% in Q1 2026, selling an estimated $27.7M and leaving 1,476,183 shares worth $432M. The position accounts for 0.05% of the portfolio, ranked #393.

Goldman Sachs first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.06B in Q4 2022. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Goldman Sachs held 1,476,183 shares of Elevance Health worth $432M as of Q1 2026.
  • Goldman Sachs sold 84,249 Elevance Health shares in Q1 2026, an estimated $27.7M.
  • Elevance Health made up 0.05% of Goldman Sachs's portfolio in Q1 2026, its #393 holding.
  • Goldman Sachs first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Elevance Health position peaked at $1.06B in Q4 2022.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.